Intravitreal bevacizumab in diabetic retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 knobloch lecture

The advent of intravitreal anti-vascular endothelial growth factor (anti-VEGF) medications has revolutionized the treatment of diabetic eye diseases. Herein, we report the outcomes of clinical studies carried out by the Pan-American Collaborative Retina Study Group (PACORES), with a specific focus o...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:

2018

Institución:

Universidad del Rosario

Repositorio:

Repositorio EdocUR - U. Rosario

Idioma:

eng

OAI Identifier:

oai:repository.urosario.edu.co:10336/23077

Acceso en línea:

https://doi.org/10.22608/APO.2017466
https://repository.urosario.edu.co/handle/10336/23077

Palabra clave:

Angiogenesis inhibitor
Bevacizumab
Adjuvant chemotherapy
Diabetic retinopathy
Human
Intravitreal drug administration
Macular edema
Preoperative care
Angiogenesis inhibitors
Bevacizumab
Diabetic retinopathy
Humans
Intravitreal injections
Macular edema
Preoperative care
Bevacizumab
Diabetic macular edema
Intravitreal injections
Proliferative diabetic retinopathy
Tractional retinal detachment
adjuvant
Chemotherapy

Rights

License

Abierto (Texto Completo)